[go: up one dir, main page]

MA34625B1 - Hydrate de tartrate de 1-((25)-2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4)pirimidin-7(6h)-yl) - Google Patents

Hydrate de tartrate de 1-((25)-2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4)pirimidin-7(6h)-yl)

Info

Publication number
MA34625B1
MA34625B1 MA35861A MA35861A MA34625B1 MA 34625 B1 MA34625 B1 MA 34625B1 MA 35861 A MA35861 A MA 35861A MA 35861 A MA35861 A MA 35861A MA 34625 B1 MA34625 B1 MA 34625B1
Authority
MA
Morocco
Prior art keywords
dihydropyrido
trifluoromethyl
bis
amino
pirimidin
Prior art date
Application number
MA35861A
Other languages
English (en)
Inventor
Ki Sook Park
Jung Min Yun
Bong Chan Kim
Kyu Young Kim
Ji Hye Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45995015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34625(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of MA34625B1 publication Critical patent/MA34625B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN HYDRATE 1,5 DE TARTRATE DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMÉTHYL)- 5,8-DIHYDROPYRIDO [3,4-D]PYRIMIDIN-7(6H)-YL]-4-OXOBUTYL}- 5,5-DIFLUOROPIPÉRIDIN-2-ONE, UN PROCÉDÉ POUR LE PRÉPARER, ET UNE COMPOSITION PHARMACEUTIQUE POUR INHIBER DPP-IV, QUI COMPREND LEDIT COMPOSÉ COMME COMPOSANT ACTIF.
MA35861A 2010-11-01 2011-10-31 Hydrate de tartrate de 1-((25)-2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4)pirimidin-7(6h)-yl) MA34625B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100107868 2010-11-01
PCT/KR2011/008186 WO2012060590A2 (fr) 2010-11-01 2011-10-31 Hydrate de tartrate de 1-{(2s)-2-amino-4-[2,4-bis(trifluorométhyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoropipéridin-2-one

Publications (1)

Publication Number Publication Date
MA34625B1 true MA34625B1 (fr) 2013-10-02

Family

ID=45995015

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35861A MA34625B1 (fr) 2010-11-01 2011-10-31 Hydrate de tartrate de 1-((25)-2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4)pirimidin-7(6h)-yl)

Country Status (29)

Country Link
US (1) US8859567B2 (fr)
EP (1) EP2635580B1 (fr)
JP (1) JP6193762B2 (fr)
KR (1) KR101446789B1 (fr)
CN (1) CN103189375B (fr)
AP (1) AP3287A (fr)
AR (1) AR083591A1 (fr)
AU (1) AU2011324253B2 (fr)
BR (1) BR112013010586A2 (fr)
CA (1) CA2814357C (fr)
CL (1) CL2013001137A1 (fr)
CO (1) CO6710945A2 (fr)
DO (1) DOP2013000090A (fr)
EA (1) EA024679B1 (fr)
EC (1) ECSP13012599A (fr)
GE (1) GEP20156218B (fr)
IL (1) IL225808A (fr)
MA (1) MA34625B1 (fr)
MX (1) MX341584B (fr)
MY (1) MY156428A (fr)
NZ (1) NZ609644A (fr)
PE (3) PE20240220A1 (fr)
PH (1) PH12013500685A1 (fr)
SG (1) SG189931A1 (fr)
TW (1) TWI519533B (fr)
UA (1) UA106445C2 (fr)
UY (1) UY33696A (fr)
WO (1) WO2012060590A2 (fr)
ZA (1) ZA201302646B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95949C2 (ru) 2006-03-31 2011-09-26 Янссен Фармацевтика, Н.В. Бензоимидазол-2-илпиримидины и пиразины как модуляторы рецептора гистамина h4
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
HRP20200253T1 (hr) 2013-03-06 2020-05-29 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora
KR102760956B1 (ko) * 2020-10-13 2025-02-03 주식회사 엘지화학 제미글립틴 및 다파글리플로진을 포함하는 경구용 복합제제, 및 이의 제조 방법
KR20250137744A (ko) 2024-03-11 2025-09-19 엠에프씨 주식회사 제미글립틴의 신규 결정형 및 이의 제조방법
KR20250147756A (ko) 2024-03-27 2025-10-14 엠에프씨 주식회사 신규한 형태의 제미글립틴 말산염 결정형 및 이의 제조방법
KR20250155700A (ko) 2024-04-24 2025-10-31 주식회사 다산제약 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물
CN119285630B (zh) * 2024-09-05 2025-05-27 安徽峆一药业股份有限公司 一种吉格列汀草酸盐及其晶型、制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208498B2 (en) * 2002-07-15 2007-04-24 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2004210149A1 (en) * 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth

Also Published As

Publication number Publication date
KR101446789B1 (ko) 2014-10-01
UY33696A (es) 2012-04-30
GEP20156218B (en) 2015-01-12
JP6193762B2 (ja) 2017-09-06
AP2013006866A0 (en) 2013-05-31
PE20240220A1 (es) 2024-02-16
CA2814357A1 (fr) 2012-05-10
MX341584B (es) 2016-08-25
MX2013004776A (es) 2013-11-04
EP2635580B1 (fr) 2015-08-12
AU2011324253B2 (en) 2015-10-29
TWI519533B (zh) 2016-02-01
EA024679B1 (ru) 2016-10-31
ECSP13012599A (es) 2013-07-31
UA106445C2 (ru) 2014-08-26
US8859567B2 (en) 2014-10-14
MY156428A (en) 2016-02-26
IL225808A0 (en) 2013-06-27
PE20180464A1 (es) 2018-03-06
EP2635580A2 (fr) 2013-09-11
CN103189375B (zh) 2016-08-10
WO2012060590A3 (fr) 2012-06-28
EA201390644A1 (ru) 2014-11-28
CA2814357C (fr) 2015-07-07
SG189931A1 (en) 2013-06-28
CO6710945A2 (es) 2013-07-15
PH12013500685A1 (en) 2015-10-02
EP2635580A4 (fr) 2014-04-02
CL2013001137A1 (es) 2013-09-06
IL225808A (en) 2016-08-31
TW201245189A (en) 2012-11-16
WO2012060590A2 (fr) 2012-05-10
AP3287A (en) 2015-05-31
JP2013540810A (ja) 2013-11-07
DOP2013000090A (es) 2018-06-30
NZ609644A (en) 2016-02-26
ZA201302646B (en) 2014-01-29
BR112013010586A2 (pt) 2016-08-09
CN103189375A (zh) 2013-07-03
PE20140392A1 (es) 2014-03-22
KR20120046069A (ko) 2012-05-09
US20130203787A1 (en) 2013-08-08
AR083591A1 (es) 2013-03-06
AU2011324253A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
MA34625B1 (fr) Hydrate de tartrate de 1-((25)-2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4)pirimidin-7(6h)-yl)
WO2007067506A3 (fr) Inhibiteurs d'erbb kinase de 2-pyrimidinyl-pyrazolopyridine
WO2006068826A3 (fr) Inhibiteurs de la kinase erbb a base de 2-pyrimidinyle pyrazolopyridine
WO2008131000A3 (fr) Inhibiteurs mcl-1 indole 7-substitués
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
WO2005116028A3 (fr) Heterocycles bicycliques servant d'inhibiteurs de kinase
TN2011000245A1 (en) Organic compounds
MX2013014348A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-feni]-2 -alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos.
UA93424C2 (en) Preparation of azoxystrobin
WO2012007345A3 (fr) Imidazo[1,2-a]pyrimidines et -pyridines substitués
MX2011008289A (es) Tabletas para terapia combinada.
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
TW200800967A (en) Benzimidazole thiophene compounds
NZ597203A (en) Novel phenylimidazole derivative as pde10a enzyme inhibitor
MY152018A (en) Indole derivatives as anticancer agents
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2011120912A9 (fr) Iminodérivés fongicides
WO2009097973A3 (fr) Imidazopyridazines en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments
WO2008086128A3 (fr) Aminopyrazoles inhibiteurs de kinases
MA53509A (fr) Agent thérapeutique contenant un composé pyrazolo[3,4-d]pyrimidine comme ingrédient actif
MX2009003793A (es) Inhibidores de cinasa.
WO2007143506A3 (fr) Composés d'éther benzylique de benzimidazole thiophène substitué non cyclique
UA92180C2 (en) Benzimidazole thiophene compounds as plk inhibitors
TN2013000161A1 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
UA103224C2 (ru) Таблетки для комбинированной терапии